Adicet Bio Inc (ACET)
1.675
-0.14
(-7.46%)
USD |
NASDAQ |
Apr 26, 16:00
1.675
0.00 (0.00%)
After-Hours: 20:00
Adicet Bio Research and Development Expense (Quarterly): 24.76M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 24.76M |
| September 30, 2023 | 26.17M |
| June 30, 2023 | 28.36M |
| March 31, 2023 | 26.76M |
| December 31, 2022 | 25.02M |
| September 30, 2022 | 16.57M |
| June 30, 2022 | 16.18M |
| March 31, 2022 | 13.48M |
| December 31, 2021 | 14.66M |
| Date | Value |
|---|---|
| September 30, 2021 | 11.93M |
| June 30, 2021 | 10.62M |
| March 31, 2021 | 11.74M |
| December 31, 2020 | 9.683M |
| September 30, 2020 | 8.942M |
| June 30, 2020 | 8.676M |
| March 31, 2020 | 7.033M |
| December 31, 2019 | 6.523M |
| September 30, 2019 | 6.331M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.331M
Minimum
Sep 2019
28.36M
Maximum
Jun 2023
15.19M
Average
12.70M
Median
Research and Development Expense (Quarterly) Benchmarks
| Sagimet Biosciences Inc | 5.656M |
| Catalyst Pharmaceuticals Inc | 1.972M |
| Codexis Inc | 11.23M |
| Annexon Inc | 23.27M |
| Taysha Gene Therapies Inc | 12.68M |